Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with Type 2 diabetes

Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with... Aim Metformin therapy reduces microvascular complications in Type 2 diabetes; questions remain, however, regarding its impact on macrovascular events. This study examined metformin use in relation to risk of cardiovascular‐related hospitalization and mortality. Methods We conducted a retrospective cohort analysis, using Saskatchewan Health administrative databases to identify new users of oral antidiabetic drugs. Subject groups were defined by medication use during 1991–1999: sulphonylurea monotherapy, metformin monotherapy, or combination therapy. Deaths and non‐fatal hospitalizations recorded during the study period were identified as cardiovascular‐related from ICD‐9 codes. The main outcome was a composite of first non‐fatal hospitalization or death. Standard multivariate techniques, including propensity scores, were used to adjust for potential confounding. Multivariate Cox proportional hazard models were used to examine the relationship between metformin use and the composite endpoint. Results Metformin monotherapy was associated with a lower risk of the composite endpoint (adjusted hazard ratio 0.81; 95% confidence interval 0.68, 0.97) compared with sulphonylurea monotherapy. Combination therapy with meformin and a sulphonylurea was associated with lower mortality, but had similar hospitalization rates, to sulphonylurea monotherapy. Conclusions Metformin monotherapy was associated with a lower risk of cardiovascular‐related morbidity and mortality, and combination metformin and sulphonylurea therapy was associated with a reduced risk of fatal cardiovascular events, when compared with sulphonylurea monotherapy. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Diabetic Medicine Wiley

Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with Type 2 diabetes

Download PDF
6 pages

Loading next page...
 
/lp/wiley/reduced-cardiovascular-morbidity-and-mortality-associated-with-DQhpQZhIUI

References (31)

Publisher
Wiley
Copyright
Copyright © 2005 Wiley Subscription Services, Inc., A Wiley Company
ISSN
0742-3071
eISSN
1464-5491
DOI
10.1111/j.1464-5491.2005.01448.x
pmid
15787679
Publisher site
See Article on Publisher Site

Abstract

Aim Metformin therapy reduces microvascular complications in Type 2 diabetes; questions remain, however, regarding its impact on macrovascular events. This study examined metformin use in relation to risk of cardiovascular‐related hospitalization and mortality. Methods We conducted a retrospective cohort analysis, using Saskatchewan Health administrative databases to identify new users of oral antidiabetic drugs. Subject groups were defined by medication use during 1991–1999: sulphonylurea monotherapy, metformin monotherapy, or combination therapy. Deaths and non‐fatal hospitalizations recorded during the study period were identified as cardiovascular‐related from ICD‐9 codes. The main outcome was a composite of first non‐fatal hospitalization or death. Standard multivariate techniques, including propensity scores, were used to adjust for potential confounding. Multivariate Cox proportional hazard models were used to examine the relationship between metformin use and the composite endpoint. Results Metformin monotherapy was associated with a lower risk of the composite endpoint (adjusted hazard ratio 0.81; 95% confidence interval 0.68, 0.97) compared with sulphonylurea monotherapy. Combination therapy with meformin and a sulphonylurea was associated with lower mortality, but had similar hospitalization rates, to sulphonylurea monotherapy. Conclusions Metformin monotherapy was associated with a lower risk of cardiovascular‐related morbidity and mortality, and combination metformin and sulphonylurea therapy was associated with a reduced risk of fatal cardiovascular events, when compared with sulphonylurea monotherapy.

Journal

Diabetic Medicine – Wiley

Published: Apr 1, 2005

There are no references for this article.